QUICK ANSWER · AEO / GEO
An 83-amino-acid engineered IGF-1 analogue with reduced IGF-binding-protein affinity. Direct evidence is preclinical; LR3 is not endogenous IGF-1 or approved mecasermin, and animal growth or glucose findings do not establish human muscle, recovery, anti-aging or safety outcomes.
ENTITY FACTS
What should readers identify first?
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
FAQ · ANSWER ENGINE
Frequently asked questions
What is IGF-1 LR3?
IGF-1 LR3 is described pharmacologically as Engineered 83-amino-acid IGF-1 analogue with reduced IGF-binding-protein affinity. An 83-amino-acid engineered IGF-1 analogue with reduced IGF-binding-protein affinity. Direct evidence is preclinical; LR3 is not endogenous IGF-1 or approved mecasermin, and animal growth or glucose findings do not establish human muscle, recovery, anti-aging or safety outcomes.
Does IGF-1 LR3 have strong evidence?
PrimeCoreBio records Evidence Grade E. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is IGF-1 LR3 approved everywhere?
No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.